Table 2 Multivariate regression analyses for clinical outcome and pro-inflammatory cytokines
From: Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder
| Â | Previous hospitalizations (times) | Dyskinesia (AIMS) | Insight(SAI) | Global function (GAF) | Executive function(WCST) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Standardized coefficient (ß) (95% C.I.) | P value | Standardized coefficient (ß) (95% C.I.) | P value | Standardized coefficient (ß) (95% C.I.) | P value | Standardized coefficient (ß) (95% C.I.) | P value | Standardized coefficient (ß) (95% C.I.) | P value | |
Age | −0.18 | 0.848 | 0.190 | 0.020** | −0.063 | 0.479 | −0.054 | 0.526 | −0.392 | P < 0.001** |
(−0.062,0.051) | (0.03,0.094) | (−0.092,0.043) | (−0.208,0.107) | (−0.628,-0.205) | ||||||
Gender | ||||||||||
 Male | -- | -- | -- | -- |  |  | -- | -- | -- | -- |
 Female | 0.205 | 0.021** | 0.203 | 0.020** | 0.190 | 0.026** | −0.144 | 0.079 | −0.044 | 0.653 |
(0.238,2.918) | (0.215,2.419) | (0.224,3.464) | (−7.21,0.397) | (−5.945,3.741) | ||||||
Smoking | 0.072 | 0.415 | 0.141 | 0.105 | 0.049 | 0.565 | −0.238 | 0.004** | −0.137 | 0.154 |
(−0.870,2.095) | (−0.209,2.169) | (−1.240,2.262) | (−10.170,-1.962) | (−0.9007,1.445) | ||||||
Bipolar disorder subtype | ||||||||||
 Type I | -- | -- | -- | -- |  |  | -- | -- | -- | -- |
 Type II | −0.197 | 0.028** | −0.408 | 0.684 | 0.294 | 0.001** | −0.009 | 0.911 | −0.041 | 0.670 |
(−2.775,-0.162) | (−1.305,-0.858) | (1.194,4.385) | (−3.944,3.522) | (−5.739,3.704) | ||||||
Pharmacological treatment duration (years) | 0.259 | 0.005** | 1.165 | 0.246 | 0.258 | 0.004** | 0.154 | 0.071 | 0.083 | 0.401 |
(0.028,0.153) | (−0.021,0.080) | (0.035,0.183) | (−0.014,0.332) | (−0.127,0.315) | ||||||
Psychiatric medication group | ||||||||||
 Mood stabilizers only | -- | -- | -- | -- |  |  | -- | -- | -- | -- |
 Atypical antipsychotics only | 0.185 | 0.071 | 0.094 | 0.355 | 0.054 | 0.586 | −0.321 | 0.001** | −0.219 | 0.039** |
(−0.163,3.848) | (−0.852,2.357) | (−1.707,3.006) | (−15.003,-3.928) | (−15.303,-0.396) | ||||||
 Atypical antipsychotics plus mood stabilizers | 0.089 | 0.383 | 0.049 | 0.630 | 0.139 | 0.164 | −0.312 | 0.001** | −0.218 | 0.042** |
(−0.829,2.143) | (−0.937,1.543) | (−0.534,3.124) | (−11.365,-2.805) | (−10.721,-0.196) | ||||||
Metabolic syndrome (+) | 0.19 | 0.036** | 2.190 | 0.030** | −0.179 | 0.036** | −0.164 | 0.046** | −0.324 | 0.042** |
(0.097,2.918) | (0.121,2.387) | (−3.447,-0.118) | (−7.891,-0.071) | (−9.969,-0.178) | ||||||